46 results about "Liver enzyme" patented technology

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

The invention provides means to determine the predisposition of individuals to adverse drug reactions (ADRs). The methods are based on genotyping or parallelized enzyme and protein profiling or both. Parallelized enzyme activity profiling can be used for drug screening and development. As examples of the invention we show the prediction of adverse drug reactions of pulmonary hypertension patients by identifying genes and alleles linked to known ADRs and liver enzyme reaction profiling with ADR correlation.

Disclosed is a method for detecting CYP450 enzymatic activity by means of micro-liver tissue incubation in vitro, which is characterized in that: a liver trace puncturing method used in clinic takes micro-liver tissues of 0.1 to 0.2g, or kills a mouse to take out the liver in an animal experiment, and builds a micro-liver tissue in vitro incubation system, then uses a one-probe medicine to perform the liquid phase chromatography tandem mass spectrometry for detecting probe substrates and concentration of corresponding metabolites, and obtains the activity of P450 enzyme according to metabolite ratios thereof. The method has the advantages of: 1. micro scale: only micro-liver tissues of 0.1 to 0.2g are needed for detecting cytochrome P450enzyme activity, and can be used for animal experiment and checking clinic micro-liver tissue liver drug enzyme activity; 2. time saving and convenience: costly ultracentrifugation equipment used in the conventional method is saved, costs and time for detection are greatly saved, and liver enzyme metabolic condition simulation is better; and 3. establishing indexes for evaluating the enzyme metabolic activity: metabolite ratios.

The invention discloses a goose liver essence and a preparation method of the goose liver essence. The goose liver essence comprises the following components by weight ratio: 40-60 parts of goose liver enzyme hydrolysis solution, 1-10 parts of reducing sugar, 1-15 parts of amino acid, 0.1-1.5 parts of thiamine hydrochloride, 0.1-5 parts of disodium 5'-ribonucleotide, 0.1-5 parts of spice powder and 30-45 parts of hydrolyzed vegetable protein solution. The goose liver essence is prepared from the goose liver enzyme hydrolysis solution as well as the reducing sugar, the amino acid, the thiamine hydrochloride, the disodium 5'-ribonucleotide, the spice powder and the hydrolyzed vegetable protein solution through Maillard reaction, wherein the goose liver enzyme hydrolysis solution serves as the main raw material, and the reducing sugar, the amino acid, the thiamine hydrochloride, the disodium 5'-ribonucleotide, the spice powder and the hydrolyzed vegetable protein solution serve as the auxiliary raw materials. Therefore, the prepared product has strong real goose liver characteristic aroma, mellow taste and high nutritional value and can be widely used as the essence of instant noodle seasonings, food ingredients and meat products.

It was discovered that insulin binding to insulin receptors signals the upregulation of expression of the liver enzyme deiodinase 1 (Dio1), which in turn activates the ApoA-1 promoter, thereby thereby increasing ApoA-1 expression (primarily in the liver), that in turn raises the levels of plasma ApoA-1, the major and necessary protein in HDLC. Certain embodiments of the invention are directed to methods for increasing circulating HDLC levels in an animal by administering therapeutically effective amounts of Dio1, or by increasing the level of Dio1 through gene therapy.

The present invention relates to a kind of plant oil with linoleic acid and linolenic acid in the ratio of 4 to 1, and the plant oil is mixture of five kinds of plant oil, including perilla oil, linseed oil, sunflower seed oil, soybean oil and sesame oil in undetermined proportion and contains linoleic acid in 48 wt% and linolenic acid in 12 wt%. The plant oil has increased linolenic acid, and under the action of the liver enzyme inside human body, linolenic acid will have its carbon chain elongated to become eicosapentaenoic acid, so-called 'blood vessel cleaner', and docosahexenoic acid, so-called 'brain gold'. Therefore, the present invention is significant in preventing various kinds of cardiac and cerebral vascular diseases.

Cannabis extract subjected to a Pulsed Electric Fields (PEF), High Temperature Short Time (HTST), Heat, High Pressure Processing (HPP) and weak acid preserves the cannabis extract. This process delays, maintains, inhibits, retards and/or reduces the rate of plant derived and/or synthetically derived cannabinoid extract deterioration or degradation and is ideally used in beverages, foods and other consumer products, including a juice product. In addition to preserving the product, the weak acids are preferably citric acid and lemon juice to both inhibit action of oxidative enzymes in the packaged product, but to also inhibit hepatic enzymes in vivo to improve the duration of bio-activity, improve bio-availability, and optimize bio-effects of cannabinoids.

The invention relates to a microorganism feed additive capable of protecting pig livers and a preparation method of the microorganism feed additive. All strains adopted by the microorganism feed additive are screened out from intestinal tracts of animals, and a strain compound culturing method is adopted, so that an antagonism mechanism of the strains is avoided, and fermented products are optimized; and in the whole production technology, beneficial microorganisms are furthest maximized, and a main fermented product namely glutathione is wholly recovered from intracellular and extracellular positions. According to the microorganism feed additive and the preparation method thereof disclosed by the invention, oxygen free radicals can be effectively eliminated, so that the stability of liver cell membranes is improved, the activity of liver enzymes is promoted, the absorption of iron can also be promoted, the integrity of red cell membranes can be maintained, the biosynthesis of DNA is maintained, the normal growth of cells is maintained, and cell immunity is maintained; as a micro-ecologic preparation, the microorganism feed additive can effectively promote the digestion and the absorption of the feed by the animals, the lean meat percentage is increased, toxin disoperation can be alleviated, the feed conversion rate is increased, and the production capacity of bred animals is improved.

One exemplary embodiment of the disclosure provides methods and compositions for treating a subject suffering from Alcoholic Liver Disease, Non-Alcoholic Fatty Liver Disease, type 2 diabetes, metabolic syndrome, cardiovascular disease, chronic kidney disease, and certain cancers, or a combination thereof, by administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject. In another exemplary embodiment, the disclosure provides methods and compositions for treating a subject suffering from elevated circulating concentrations of liver enzymes wherein the liver enzymes are selected from gamma glutamyl transferase, alanine amino transferase, alkaline phosphatase and complement fraction 3 or a combination thereof, the method comprising administering a therapeutically effective amount of purified liminoid glucoside or a pharmaceutically acceptable salt thereof to the subject wherein the treating results in a decreased circulating concentration of the liver enzymes.

The present application relates to an in vitro method for identifying a pregnancy related syndrome selected from the group consisting of pre-eclampsia, eclampsia, Hemolysis Elevated Liver enzymes and Low Platelets (HELLP) and intra-uterine growth restriction (IUGR), the method including (i) measuring the amount of ESM-1 in a biological fluid sample from a pregnant subject, wherein the pregnant subject is between week 1 to 20 of gestation; (ii) comparing said amount of ESM-1 to a reference value, and (iii) identifying the subject as being likely to have or develop the pregnancy related syndrome based on a comparison of the amount of ESM-1 to the reference value. A device and a kit for identifying such a pregnancy related syndrome are also claimed.

A tadalafil chewing gum and the manufacturing method and the application relate to a medical chewing gum for remedying male sexual dysfunction and the preparation method. Because of the indissolubility and the low biological utilization degree of the tadalafil, the noneffective dosage is large, and a plurality of adverse reactions occurs. The component of the tadalafil chewing gum includes a chewing gum matrix, which contains tadalafil or tadalafil slat, and the ratio of the weight portion is 100 portions of chewing gum matrix to 0.1 to 10 portions of tadalafil. The product is used for improving the administration method of the drug of tadalafil for the male sexual dysfunction and can promote the stable absorption of the drug. The drug can be directly absorbed through the sublingual vein by orally chewing, which reduces the damage towards the drug because of gastrointestinal enzyme and liver enzyme (first-pass effect) and improves the biological utilization degree and reduces the dosage of the drug; the invention can also reduce the stimulation of the drug toward the gastrointestinal tract, which reduces the occurrence of the adverse reaction and increases the safety.

The invention discloses a kudzu flower and ginseng compound anti-alcohol and liver-protecting oral liquid and a preparation method thereof. The kudzu flower and ginseng are used as the monarch medicine and supplemented with six traditional Chinese medicines of ganoderma lucidum, chrysanthemum, skullcap, astragalus, mulberry and thyme. The effective essence of traditional Chinese medicine is extracted by CO2 supercritical, and the extract powder is dried and sieved, and then 9% of the extract powder, 15% of jujube honey, 26% of fresh lotus root juice, and 50% of purified water are mixed and stirred to make an oral liquid. Taking it in time before and after drinking can enhance the function of the liver enzyme system, accelerate the decomposition of alcohol, and improve alcohol tolerance to prevent drunkenness and sobering up. Effectively relieves headache, dizziness, polydipsia and vomiting caused by alcoholism, protects and repairs liver cell damage caused by alcoholism; daily use can also nourish and protect the liver, and remove alcohol poisoning accumulated in the body for many years; it is simple and convenient to take, without side effects; and The curative effect is remarkable, the effect is quick, the course of treatment is short, and the total effective rate reaches 100%.

The invention relates to an immunoassay for evaluating liver diseases or functions by virtue of a nursing point. The immunoassay comprises the following steps: (i) enabling a blood sample coming froma human subject to be contacted with a specific binding agent used for identifying an epitope of a liver enzyme or metabolite, so as to form an antigen-binding agent composite, and detecting the composite by using a second binding agent connected with a detectable reporter, wherein a rodent antibody can not identify the epitope in presence of human blood plasma; and (ii) detecting the liver diseases or functions in the subject according to mass concentration of the liver enzyme or metabolite in the sample.

The invention discloses a preparation method of a duck fatty liver oil. The method specifically includes the steps of: (1) preparation of duck fatty liver slurry: chopping duck fatty liver and performing tissue homogenization to obtain a slurry; (2) duck fatty liver enzymolysis: mixing the slurry and a buffer solution according to a ratio of 1:0-2.5, and adding protease for enzymolysis of the slurry; and (3) extraction of duck fatty liver oil: after enzymolysis, mixing the slurry with petroleum ether, then performing ultrasonic extraction, then carrying out high speed centrifugation, taking the supernatant and performing filtering, and utilizing a vacuum rotary evaporator to remove petroleum ether from the filtrate. The invention adopts an ultrasonic assisted enzymatic extraction method to prepare duck fatty liver oil, and the method has the advantages of full extraction of grease from duck fatty liver, reduction of temperature, time saving, simple process, and high maneuverability.

The innovation is directed to a method for treating a CCR5 and/or CCR2 mediated disease such as nonalcoholic steatohepatitis (NASH) comprising administering an effective amount of a C-C Chemokine receptor 5 (CCR5) antagonist (e.g., maraviroc or vicriviroc or cenicriviroc) and/or an effective amount of a C-C Chemokine receptor 2 (CCR2) antagonist, or a CCR5/CCR2 antagonist together with an effective amount of farnesoid X receptor (FXR) agonist (e.g., obeticholic acid (OCA)). An “effective amount” can be a regular clinical dose of either agent alone or a reduced dose of the FXR receptor agonist and/or the CCR5/CCR2 antagonist. The combination is effective to treat NASH with (1) enhanced efficacy and (2) substantial reduction of side effects, particularly those associated with administration of OCA or its analogues, namely less effect on liver enzyme elevation, and less severity and frequency of pruritus (3). The fixed dose combination provides for better efficacy and safety profile.